Primary efficacy results from phase I and III trials demonstrate clinically meaningful efficacy and favorable safety profile of asciminib in patients with chronic myeloid leukemia (CML)‐chronic phase (a phase III, open‐label, randomized study of asciminib, a STAMP inhibitor, vs. bosutinib in CML after two or more prior TKIs). This evidence concerns the gene TTLL5 and chronic myelogenous leukemia, BCR-ABL1 positive.